Regulation S-K

Form 8.3 - The Vanguard Group, Inc.: Aon plc

Monday, March 1, 2021 - 3:05pm

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.

Form 8.3 - The Vanguard Group, Inc.: Willis Towers Watson plc

Monday, March 1, 2021 - 3:05pm

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.

Form 8.3 - Tibra Trading PTY Limited: APPLEGREEN PLC

Monday, March 1, 2021 - 3:05pm

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.

Form 8.3 - The Vanguard Group, Inc.: Willis Towers Watson plc

Friday, February 26, 2021 - 3:06pm

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.

Form 8.3 - The Vanguard Group, Inc.: Aon plc

Friday, February 26, 2021 - 3:05pm

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.

Streamline Health Announces Pricing of Upsized $14 Million Public Offering of Common Stock

Friday, February 26, 2021 - 12:30pm

Additionally, in connection with the offering, Streamline Health granted the underwriter a 30-day option to purchase up to an additional 1,312,500 shares of its common stock on the same terms and conditions.

Key Points: 
  • Additionally, in connection with the offering, Streamline Health granted the underwriter a 30-day option to purchase up to an additional 1,312,500 shares of its common stock on the same terms and conditions.
  • All of the securities in the offering are being sold by Streamline Health.
  • The gross proceeds from the offering to Streamline Health are expected to be $14.0million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Streamline Health, but excluding any exercise of the underwriters option to purchase additional shares of common stock.
  • Streamline Health intends to use the net proceeds from the offering for working capital and general corporate purposes.

PAVmed Announces Closing of its Public Offering of Common Stock

Thursday, February 25, 2021 - 5:37pm

NEW YORK, Feb. 25, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the Company or PAVmed), a highly differentiated, multi-product, commercial-stage medical device company, today announced the closing of its previously announced underwritten public offering (the Offering) of approximately 9.8 million shares of its common stock for gross proceeds of approximately $45 million, before deducting underwriting discounts and commissions and other offering expenses payable by PAVmed.

Key Points: 
  • NEW YORK, Feb. 25, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the Company or PAVmed), a highly differentiated, multi-product, commercial-stage medical device company, today announced the closing of its previously announced underwritten public offering (the Offering) of approximately 9.8 million shares of its common stock for gross proceeds of approximately $45 million, before deducting underwriting discounts and commissions and other offering expenses payable by PAVmed.
  • The underwriter has a 30-day option to purchase up to approximately 1.5 million additional shares of PAVmeds common stock.
  • A prospectus supplement relating to the Offering and the accompanying prospectus have been filed with the SEC.
  • Copies of the final prospectus supplement and accompanying base prospectus relating to the Offering may be obtained from the SEC at http://www.sec.gov .

Form 8.3 - The Vanguard Group, Inc.: Willis Towers Watson plc

Thursday, February 25, 2021 - 3:06pm

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.

Form 8.3 - The Vanguard Group, Inc.: Aon plc

Thursday, February 25, 2021 - 2:11pm

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.

Univest Securities, LLC. Announces Closing of $12.5 Million Underwritten Public Offering for its Client Glory Star New Media Group Holdings Limited (Nasdaq: GSMG)

Wednesday, February 24, 2021 - 9:30pm

After deducting underwriting discounts and commissions and other estimated offering expenses, the net proceeds of the public offering were approximately $11.3 million.

Key Points: 
  • After deducting underwriting discounts and commissions and other estimated offering expenses, the net proceeds of the public offering were approximately $11.3 million.
  • The Company intends to use the net proceeds from the offering primarily for working capital and other general corporate purposes.
  • The ordinary shares and warrants were offered pursuant to an effective shelf registration statement on Form F-3 (File No.
  • Glory Star New Media Group Holdings Limited is a leading mobile entertainment operator in China.